Disposition of 184 shares by Chopas James George of Apellis Pharmaceuticals at 56.461 subject to Rule 16b-3
| APLS Stock | USD 26.33 0.57 2.12% |
Slightly above 61% of Apellis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Apellis Pharmaceuticals suggests that many traders are alarmed. Apellis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Apellis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Apellis |
Filed transaction by Apellis Pharmaceuticals Officer: Vp/chief Accounting Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Apellis Pharmaceuticals Fundamental Analysis
We analyze Apellis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Apellis Pharmaceuticals is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Apellis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Apellis Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Apellis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Apellis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Apellis Pharmaceuticals Related Equities
| MDGL | Madrigal Pharmaceuticals | 14.99 | ||||
| AMLX | Amylyx Pharmaceuticals | 4.58 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| IMVT | Immunovant | 1.52 | ||||
| TERN | Terns Pharmaceuticals | 1.35 | ||||
| AKRO | Akero Therapeutics | 0.25 | ||||
| BPMC | Blueprint Medicines | 0.15 | ||||
| MREO | Mereo BioPharma | 2.78 | ||||
| ABOS | Acumen Pharmaceuticals | 2.99 | ||||
| XFOR | X4 Pharmaceuticals | 6.82 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.